Cancer Biomarkers: Minimal and Noninvasive Early Diagnosis and Prognosis

Przednia okładka
Debmalya Barh, Angelo Carpi, Mukesh Verma, Mehmet Gunduz
CRC Press, 30 sty 2014 - 951

Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers.

It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information.

Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume

The book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers.

Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis

  • Presents noninvasive early molecular markers in urological cancers
  • Describes gynecological and endocrine cancer markers
  • Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers
  • Addresses hematological malignancies
  • Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myeloma
  • Provides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanoma

This text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.

 

Co mówią ludzie - Napisz recenzję

Nie znaleziono żadnych recenzji w standardowych lokalizacjach.

Spis treści

Quality Control and Ethical Issues of Cancer Biomarker Discovery
3
Imaging Techniques in Cancer Diagnosis
19
Role of PET in Cancer Diagnosis
39
Innovative Tools for Early Detection of Cancer
47
Noninvasive Nanodiagnostics for Cancer
85
Mitochondrial DNA in Early Cancer Diagnosis and Screening
95
Circulating miRNA Biomarkers in Various Solid Cancers
115
Stem Cell Biomarkers in Early Diagnosis Prognosis and Therapy of Cancer
143
Exhaled Volatile Organic Compounds as Noninvasive Early Molecular Markers in Lung Cancer Bridging the Gap from Bench to Bedside
433
Noninvasive Early Molecular Biomarkers in Kidney Cancer
467
Novel Oncomarkers Used for Earlier Detection of Bladder Carcinoma
491
Screening for Prostate Cancer New Markers and Future Aspects
517
Early Biomarkers in Breast Cancer
545
Noninvasive Biomarkers in Ovarian Cancer
615
Early Markers for Neoplastic Lesions of the Uterine Cervix
643
Biomarkers in Diagnosis of Papillary Thyroid Carcinoma
679

Salivary Biomarkers in Early Diagnosis and Monitoring of Cancer
159
Biomarkers for Brain Gliomas
199
Noninvasive Biomarkers in Head and Neck Squamous Cell Carcinoma
219
Biological Markers in Oral Squamous Cell Carcinoma
249
Biomarkers for Gastric Cancer and the Related Premalignant Conditions
289
Biomarkers in Esophageal Adenocarcinoma
321
Biomarkers for Diagnosis and Metastasis of Hepatocellular Carcinoma
337
Noninvasive Early Markers in Gallbladder Cancer
355
Noninvasive Early Markers in Pancreatic Cancer
383
Noninvasive Early Markers in Lung Cancer
415
Biomolecular Markers for Improving Management of Follicular and Medullary Thyroid Cancer
751
Biomarkers in Myelodysplastic Syndrome
783
Markers for Diagnosis Prognosis and Therapy of Acute Myeloid Leukemia
813
Biomarkers in Hodgkins Lymphoma
849
Multiple Myeloma and Evolution of Novel Biomarkers and Therapies
871
Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma
911
Insert
929
Back Cover
945
Prawa autorskie

Inne wydania - Wyświetl wszystko

Kluczowe wyrazy i wyrażenia

Informacje o autorze (2014)

Debmalya Barh (MSc, MTech, MPhil, PhD, PGDM) is the founder and president of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. He is a consultant biotechnologist and an active researcher in integrative omics–based biomarkers, targeted drug discovery, and personalized medicine in cancer, neurodisorders, and cardiovascular, infectious, and metabolic diseases. He works with nearly 400 esteemed researchers from 30–35 countries and he has more than 100 high-impact publications. He has edited ten books in the field of omics. He also serves as an editorial and review board member for several highly respected international journals.

Dr. Angelo Carpi is a clinical professor of medicine at the Pisa University Medical School, Pisa, Italy. He received his MD and postgraduate diplomas in internal medicine and nuclear medicine from the University of Pisa and his diploma of qualification on peptide hormones from the Collegio Medico Giuridico-Scuola Normale Superiore and the Scuola Superiore Sant’Anna, Pisa, Italy. His clinical practice and research included thyroid and breast tumors. He has authored about 300 publications included in PubMed. He is a member of the editorial boards of international journals such as Biomedicine & Pharmacotherapy and Frontiers in Bioscience.

Dr. Mukesh Verma is a program director and chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Verma received his MSc from Pantnagar University and his PhD from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 128 research articles, book chapters, and reviews, and has edited three books in the field of cancer epigenetics and epidemiology.

Mehmet Gunduz, MD, PhD, is a professor of otolaryngology and medical genetics, Faculty of Medicine, Turgut Ozal University, Turkey. He graduated from Medical School Hacettepe University in 1990, and completed his residency in otolaryngology at the same university. He received his PhD from Okayama University and Wakayama Medical University, Japan, and is medical board certified from both the Turkish and Japanese certification authorities. One of the pioneers in identifying ING family tumor suppressors, Dr. Gunduz has contributed to more than 150 international publications, 3,000 citations, several book chapters, and over 200 presentations in national and international conferences.

Informacje bibliograficzne